If you've ever taken a high-school biology class, you've heard mitochondria called "the powerhouse of the cell." They turn the food you eat into energy your body can use. SS-31 (also called Elamipretide) is a peptide designed to head straight for these tiny power plants.
How it gets in
SS-31 has a positive electrical charge that pulls it into mitochondria, which carry a slight negative charge inside. Once there, it binds to a fatty molecule called cardiolipin. Cardiolipin lives in the mitochondrial inner membrane, and when it gets damaged, the whole energy-making machine works less efficiently.
What's been studied
Researchers have looked at SS-31 in models of heart failure, kidney disease, and age-related muscle weakness — all conditions where mitochondrial trouble shows up. In animal studies, SS-31 appeared to preserve cardiolipin structure, reduce reactive oxygen species (the cellular form of "rust"), and protect ATP production.
Human clinical trials have explored its potential for primary mitochondrial diseases and ischemia-reperfusion injury, with mixed but informative results.
Why scientists care
Most drugs can't cross into mitochondria efficiently. SS-31 can. That makes it a unique tool for asking, "what happens if we directly support these energy factories?" — a question with real implications for many age-related conditions.
Important: SS-31 is sold for laboratory and research use only. It is not for human consumption.